$4 million grant from Mirati Therapeutics to support SU2C research on KRAS mutant cancers

LOS ANGELES AND SAN DIEGO, CA – April 19, 2021 – Stand Up To Cancer® (SU2C) and Mirati Therapeutics Inc. (NASDAQ: MRTX) – a late-stage targeted oncology company – today announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.

The research will focus on cancer types with unmet medical needs, and the application of tumor-agnostic strategies and molecular testing to address those needs. Certain cancers can sometimes have mutations in the KRAS gene, which makes a protein involved in cellular growth and death. In KRAS mutant cancers, that protein can cause cancers to grow and spread. KRAS proteins were once considered undruggable, but recent research advances have resulted in the identification and development of investigational drugs against cancers that have specific KRAS mutations. Preliminary data from these investigational drugs have demonstrated early signs of clinical activity and studies are ongoing.

The grant from Mirati will leverage the SU2C Catalyst innovative research process, which uses funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment. The research will explore new treatment strategies with a KRASG12C inhibitor currently being developed by Mirati.

“The SU2C Catalyst program encourages a collaborative yet nimble and transparent process that accelerates the pace of research and identifies new or unexpected uses for cancer drugs and technologies,” said Nobel laureate Phillip A. Sharp, PhD, chair of Stand Up To Cancer’s Scientific Advisory Committee and an institute professor at the David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology. “Combined with our rigorous review and milestone-driven process, the program provides a unique framework with the objective to get treatments to patients as quickly and safely as possible.”

SU2C’s Catalyst program began in 2016, with contributions from industry supporters Merck, Bristol Myers Squibb and Genentech, a member of the Roche Group. Through the program, companies donate funds to collaborative research studies, in which use of the companies’ products and materials is strongly encouraged. Those materials might include new pharmaceutical compounds that companies are developing or approved agents that can be investigated for other uses. A primary goal of SU2C Catalyst is to encourage collaborative research between academics and companies and shorten the time it takes to get new treatments to patients.

“We are excited to collaborate with Mirati Therapeutics and are thankful for their contribution to the SU2C Catalyst program,” said Sung Poblete, PhD, RN, CEO of Stand Up To Cancer. “The opportunity to test the utility of KRAS inhibitors in several different cancer types is a great example of SU2C’s cancer-agnostic approach to research.”

“We are proud to support the SU2C Catalyst program and the innovative research it makes possible,” said Joseph Leveque, M.D., executive vice president and chief medical officer, Mirati Therapeutics, Inc. “So much progress has been made in understanding and treating cancers through collaborative research. Industry and academic scientists, working together, offer the best chance to move ideas forward that can make a real difference for patients.”

As a part of the collaboration with Mirati, SU2C will convene a day-long innovation summit to bring together experts in KRAS signaling, clinical trial design, tumor agnostic approaches to cancer therapy development and other disciplines. The summit will be headed by members of SU2C’s scientific leadership team as well as Mirati representatives. These experts will consider the most pressing research needs in the field and define a grants process that provides a pathway for applicants, and the eventual grantees, to address those issues. Attention will be given to the current state of KRAS genetic testing in different cancer types and approaches that may be considered to appropriately expand testing both across tumor types and among traditionally underserved and minority populations.

###

Media Contact:

Mirabai Vogt-James Priyanka Shah

Stand Up To Cancer Mirati Media Relations

[email protected] [email protected]

Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation, a 501(c)(3) charitable organization, was established in 2008 by media and entertainment leaders who utilize these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of January 2021, more than 1,950 scientists representing more than 210 institutions are involved in SU2C-funded research projects.

Under the direction of our Scientific Advisory Committee, led by Nobel laureate Phillip A. Sharp, Ph.D., SU2C implements rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and ensure collaboration across research programs.

Current members of the SU2C Founders and Advisors Committee (FAC) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, Ph.D., R.N., serves as SU2C’s CEO.

For more information, visit StandUpToCancer.org.

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati’s vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati Therapeutics, visit us at Mirati.com or follow us on Twitter and LinkedIn.